title: A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors.
abstract: OBJECTIVE
  To obtain an optimal premedication protocol for paclitaxel liposome (Lipusu) in the treatment of solid tumors.
  
  
  METHODS
  From February 2005 to September 2007, 53 patients with advanced non-small-cell lung cancer (16 cases), breast cancer (14 cases), esophagus cancer (six cases), gastric cancer (16 cases), head and neck cancer (one case) were recruited from the Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute. Lipusu was delivered at 175 mg/m(2) (triweekly or divided into weekly) as a component of combined chemotherapy. Several premedications were attempted (detailed in the text).
  
  
  RESULTS
  The toxicity profile of premedications included: insomnia (five cases), dysphoria (three cases), hyperglycemia (two cases), fatigue (two cases), abdominal distension (one case), and vertigo (one case). No treatment-related death occurred.
  
  
  CONCLUSIONS
  Our recommendations for the premedication of Lipusu in the treatment of solid tumors are: (1) methylprednisolone 40 mg, administered intravenously 30 min before Lipusu, and granisetron 30 min before chemotherapy, (2) dexamethasone 2.25-3 mg taken orally 12 h and 2 h before Lipusu, and granisetron 30 min before chemotherapy.
authors.affiliation: Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute, Bai Zi Tin 42, Nanjing 210009, Jiangsu Province, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhang
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Gao
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage; D000932:Antiemetics / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005938:Glucocorticoids / Q000008:administration & dosage; D017829:Granisetron / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008081:Liposomes; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D011292:Premedication; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018943:Anthracyclines; D000932:Antiemetics; D000972:Antineoplastic Agents, Phytogenic; D002945:Cisplatin; D003520:Cyclophosphamide; D003907:Dexamethasone; D005472:Fluorouracil; D005938:Glucocorticoids; D017829:Granisetron; D008081:Liposomes; D008775:Methylprednisolone; D017239:Paclitaxel